awmsg logo



entecavir (Baraclude®)


Reference No. 2546

Publication date:
20/05/2015


Appraisal information

entecavir (Baraclude®) 0.5 mg film-coated tablet
entecavir (Baraclude®) 0.05 mg/ml oral solution
entecavir (Baraclude®) 1 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 25/02/2015
AWMSG meeting date: 25/03/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0715
Ministerial ratification: 15/05/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Entecavir (Baraclude®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B virus (HBV) infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase (ALT) levels, or histological evidence of moderate to severe inflammation and/or fibrosis.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download